Compare Stocks: GKOS, DXCM, RMD, and GEHC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$85.36 -1.0%	$86.70	$54.11 ▼ $92.59	$32.21B	1.48	4.10 million shs	2.18 million shs
GEHC GE HealthCare Technologies	$64.29 +0.5%	$68.88	$58.75 ▼ $89.77	$29.04B	0.73	3.52 million shs	3.24 million shs
GKOS Glaukos	$163.42 +0.2%	$172.46	$73.16 ▼ $191.62	$9.66B	0.69	830,287 shs	704,737 shs
RMD ResMed	$218.90 -1.0%	$224.02	$180.26 ▼ $284.87	$31.58B	0.75	1.18 million shs	881,621 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	0.00%	-1.45%	-4.85%	+19.80%	+29.18%
GEHC GE HealthCare Technologies	0.00%	-3.51%	-7.79%	-1.95%	-14.86%
GKOS Glaukos	0.00%	+5.74%	-9.18%	+10.80%	+96.79%
RMD ResMed	0.00%	-1.48%	-4.37%	+4.55%	-19.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$85.36 -1.0%	$86.70	$54.11 ▼ $92.59	$32.21B	1.48	4.10 million shs	2.18 million shs
GEHC GE HealthCare Technologies	$64.29 +0.5%	$68.88	$58.75 ▼ $89.77	$29.04B	0.73	3.52 million shs	3.24 million shs
GKOS Glaukos	$163.42 +0.2%	$172.46	$73.16 ▼ $191.62	$9.66B	0.69	830,287 shs	704,737 shs
RMD ResMed	$218.90 -1.0%	$224.02	$180.26 ▼ $284.87	$31.58B	0.75	1.18 million shs	881,621 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	0.00%	-1.45%	-4.85%	+19.80%	+29.18%
GEHC GE HealthCare Technologies	0.00%	-3.51%	-7.79%	-1.95%	-14.86%
GKOS Glaukos	0.00%	+5.74%	-9.18%	+10.80%	+96.79%
RMD ResMed	0.00%	-1.48%	-4.37%	+4.55%	-19.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXCM DexCom	2.92	Moderate Buy	$89.74	5.13% Upside
GEHC GE HealthCare Technologies	2.50	Moderate Buy	$78.39	21.93% Upside
GKOS Glaukos	2.80	Moderate Buy	$180.54	10.47% Upside
RMD ResMed	2.44	Hold	$241.69	10.41% Upside

Current Analyst Ratings Breakdown

Latest GKOS, DXCM, RMD, and GEHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2026	DXCM DexCom	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$90.00 ➝ $105.00
9/22/2026	GKOS Glaukos	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$190.00 ➝ $210.00
9/22/2026	GEHC GE HealthCare Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$93.00
9/22/2026	GEHC GE HealthCare Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$93.00
9/18/2026	DXCM DexCom	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$93.00 ➝ $102.00
9/18/2026	DXCM DexCom	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$95.00
9/17/2026	GEHC GE HealthCare Technologies	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$79.00
9/15/2026	RMD ResMed	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sector Perform ➝ Outperform	$244.00 ➝ $262.00
9/10/2026	RMD ResMed	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/31/2026	RMD ResMed	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$255.00 ➝ $267.00
8/20/2026	GKOS Glaukos	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$193.00 ➝ $202.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXCM DexCom	$4.66B	6.91	$2.77 per share	30.83	$7.04 per share	12.13
GEHC GE HealthCare Technologies	$20.63B	1.41	$5.88 per share	10.94	$22.80 per share	2.82
GKOS Glaukos	$612.84M	15.73	N/A	N/A	$11.42 per share	14.31
RMD ResMed	$5.65B	5.59	$12.94 per share	16.92	$45.40 per share	4.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXCM DexCom	$836.30M	$2.53	33.74	27.71	1.43	20.12%	35.94%	14.75%	10/29/2026 (Estimated)
GEHC GE HealthCare Technologies	$2.08B	$4.36	14.75	11.88	1.70	9.33%	20.12%	5.74%	11/4/2026 (Estimated)
GKOS Glaukos	-$187.69M	-$3.25	N/A	320.43	N/A	-30.68%	-6.37%	-4.78%	11/4/2026 (Estimated)
RMD ResMed	$1.52B	$10.43	20.99	16.70	1.38	26.94%	25.58%	18.89%	10/29/2026 (Estimated)

Latest GKOS, DXCM, RMD, and GEHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	DXCM DexCom	$0.6720	N/A	N/A	N/A	$1.33 billion	N/A
10/29/2026	Q1 2027	RMD ResMed	$2.68	N/A	N/A	N/A	$1.39 billion	N/A
8/6/2026	Q4 2026	RMD ResMed	$2.89	$2.95	+$0.06	$2.64	$1.46 billion	$1.46 billion
7/30/2026	Q2 2026	DXCM DexCom	$0.6110	$0.70	+$0.0890	$0.64	$1.29 billion	$1.31 billion
7/29/2026	Q2 2026	GEHC GE HealthCare Technologies	$1.04	$1.13	+$0.09	$1.24	$5.26 billion	$5.30 billion
7/29/2026	Q2 2026	GKOS Glaukos	-$0.2105	-$0.14	+$0.0705	-$0.31	$150.93 million	$185.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
GEHC GE HealthCare Technologies	$0.14	0.22%	N/A	3.21%	1 Years
GKOS Glaukos	N/A	N/A	N/A	N/A	N/A
RMD ResMed	$2.64	1.21%	+9.00%	25.31%	13 Years

Latest GKOS, DXCM, RMD, and GEHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/22/2026	GEHC GE HealthCare Technologies	quarterly	$0.04	0.24%	10/23/2026	10/23/2026	11/13/2026
8/6/2026	RMD ResMed	quarterly	$0.66	1.15%	8/20/2026	8/20/2026	9/24/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXCM DexCom	0.47	1.73	1.43
GEHC GE HealthCare Technologies	0.92	1.26	0.97
GKOS Glaukos	0.10	5.04	4.46
RMD ResMed	0.06	3.10	2.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXCM DexCom	97.75%
GEHC GE HealthCare Technologies	82.06%
GKOS Glaukos	99.04%
RMD ResMed	54.98%

Insider Ownership

Company	Insider Ownership
DXCM DexCom	0.28%
GEHC GE HealthCare Technologies	0.36%
GKOS Glaukos	5.90%
RMD ResMed	0.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXCM DexCom	11,000	377.36 million	376.30 million	Optionable
GEHC GE HealthCare Technologies	54,000	451.69 million	450.06 million	Optionable
GKOS Glaukos	1,094	58.98 million	55.50 million	Optionable
RMD ResMed	11,370	144.25 million	143.31 million	Optionable

GKOS, DXCM, RMD, and GEHC Headlines

Recent News About These Companies

Will ResMed (ASX:RMD) stay a fund manager favourite?

October 2 at 6:55 PM | kalkinemedia.comK

ResMed Inc. $RMD Shares Sold by Envestnet Asset Management Inc.

October 2 at 3:12 AM | marketbeat.com

ResMed CFO Awarded Performance-Based Equity Grant

October 1 at 7:10 PM | tipranks.com

ResMed CEO Farrell Earns Performance-Based Stock Grant

October 1 at 7:10 PM | tipranks.com

ResMed Awards Performance-Based Stock Units to Chief Product Officer

October 1 at 7:10 PM | tipranks.com

Resmed Sets Date for First-Quarter Fiscal 2027 Earnings Release and Webcast

October 1 at 6:50 PM | tipranks.com

ResMed Sets 2026 Virtual Annual Meeting and Key Governance Votes

October 1 at 6:50 PM | tipranks.com

Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026

October 1 at 4:05 PM | globenewswire.com

Is the ResMed share price a cheap buy?

September 29, 2026 | msn.com

ResMed Inc. (NYSE:RMD) Stock Has Consensus Price Target of $241.69

September 26, 2026 | americanbankingnews.com

ResMed Inc. (NYSE:RMD) Receives Consensus Recommendation of "Hold" from Brokerages

September 26, 2026 | marketbeat.com

ResMed stock slips 0.73 percent ahead of the open

September 23, 2026 | ad-hoc-news.deA

ResMed Inc. $RMD Shares Purchased by State Street Corp

September 23, 2026 | marketbeat.com

ResMed Inc. $RMD Shares Sold by Baird Financial Group Inc.

September 23, 2026 | marketbeat.com

ResMed stock holds gains as analysts highlight sleep apnea growth

September 21, 2026 | ad-hoc-news.deA

ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand

September 21, 2026 | marketbeat.com

ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures

September 20, 2026 | finance.yahoo.com

ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures

September 19, 2026 | insidermonkey.com

Nykredit A S Makes New Investment in ResMed Inc. $RMD

September 19, 2026 | marketbeat.com

Bank of America Corp DE Buys New Stake in ResMed Inc. $RMD

September 18, 2026 | marketbeat.com

Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)?

September 16, 2026 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS, DXCM, RMD, and GEHC Company Descriptions

DexCom NASDAQ:DXCM

$85.36 -0.87 (-1.01%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$85.36 +0.00 (+0.01%)

As of 10/2/2026 07:53 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

GE HealthCare Technologies NASDAQ:GEHC

$64.29 +0.31 (+0.48%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$64.25 -0.04 (-0.06%)

As of 10/2/2026 07:33 PM Eastern

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Glaukos NYSE:GKOS

$163.42 +0.25 (+0.15%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$163.74 +0.32 (+0.20%)

As of 10/2/2026 07:30 PM Eastern

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

ResMed NYSE:RMD

$218.90 -2.25 (-1.02%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$218.94 +0.04 (+0.02%)

As of 10/2/2026 07:30 PM Eastern

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GKOS, DXCM, RMD, and GEHC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GKOS, DXCM, RMD, and GEHC Earnings

Compare Dividends

Latest GKOS, DXCM, RMD, and GEHC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GKOS, DXCM, RMD, and GEHC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS, DXCM, RMD, and GEHC Company Descriptions

DexCom NASDAQ:DXCM

GE HealthCare Technologies NASDAQ:GEHC

Glaukos NYSE:GKOS

ResMed NYSE:RMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GKOS, DXCM, RMD, and GEHC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GKOS, DXCM, RMD, and GEHC Earnings

Compare Dividends

Latest GKOS, DXCM, RMD, and GEHC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GKOS, DXCM, RMD, and GEHC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS, DXCM, RMD, and GEHC Company Descriptions

DexCom NASDAQ:DXCM

GE HealthCare Technologies NASDAQ:GEHC

Glaukos NYSE:GKOS

ResMed NYSE:RMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools